Phone:020-31155029| Tech Support:tech@tomums.cn| E-mail:sales@tomums.cn
首页 > 产品 > 活性小分子 > Cell Cycle > Milciclib (PHA-848125)

Milciclib (PHA-848125)

商品编号: TS1138
图示 货号 库存 价格(¥) 数量

备注:

如需更大包装,请联系销售人员,大包装有极大的折扣优惠!

质量文档

详细介绍

l  基本信息

产品名称

Milciclib

一般描述

Milciclib is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7.

别 称

PHA-848125; N,1,4,4-tetramethyl-8-[4-(4-methylpiperazin-1-yl)anilino]-5H-pyrazolo[4,3-h]quinazoline-3-carboxamide

纯 度

≥98.0%(HPLC)

CAS NO.

802539-81-7

分子式

C25H32N8O

分子量

460.586

适用范围

生物试剂,适用于细胞培养等

l  理化信息

外 观

固体

溶解性(25°C)

DMSO

≥50mg/mL

乙醇

Insoluble

Insoluble

l  生物学信息

生物活性/药理作用

Milciclib is an orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and tropomyosin receptor kinase  A (TRKA), with potential antineoplastic activity. CDK2/TRKA inhibitor PHA-848125 AC potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some cancer cell types. The neurotrophin receptor TRKA is mutated in a variety of cancer cell types.

l  存储

存储温度

-20°C

l  注意事项及免责声明

本产品仅用于实验研究,不得作为药物使用,不得用于家用或其它用途。

l  参考文献

1.    http://www.drugbank.ca

2.    https://ncit.nci.nih.gov

3.    https://www.ncbi.nlm.nih.gov